All In Biotech

Drug Trial Radar · NCT07101627

A Prospective, Multicenter Clinical Study of Hetrombopag in the Prevention of Thrombocytopenia Caused by Lung Cancer Therapy

Last checked: Nov 19, 2026Latest source record: Aug 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 149 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

149

Planned (sponsor's estimate)

Start

Aug 1, 2025

Primary completion

Apr 30, 2027

Study completion Jun 30, 2027

Sponsor

Lead sponsor
Shanghai Pulmonary Hospital, Shanghai, ChinaAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Jiangsu HengRui Medicine Co., Ltd.
First posted
Aug 3, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the efficacy and safety of Hetrombopag in secondary prevention of thrombocytopenia caused by lung cancer treatment

Conditions

  • Lung Cancer

Interventions

  • Hetrombopag TabletsDrug

    Stage 1: After screening and enrollment, patients will receive oral administration of hetrombopag, 7.5 mg/day, for 14 days from the first day after the end of chemotherapy in this cycle. Stage 2: Patients who met the inclusion criteria were randomized 1:1 to the experimental group and the control group after enrollment. Patients in the experimental group began to orally take hetrombopag 7.5 mg/day for 14 days on the first day after the end of chemotherapy in this cycle; patients in the control group began to orally take hetrombopag simulated tablets 7.5 mg/day for 14 days on the first day after the end of chemotherapy in this cycle. Randomization was stratified by concomitant immunotherapy (yes versus no) and chemotherapy with gemcitabine plus platinum (yes versus no).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Grade 3 and Higher ThrombocytopeniaTime frame: One cycle of treatment(21 days)

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Jiangsu Cancer Hospital

    Nanjing, Jiangsu, China

  • Shanghai Pulmonary Hospital, Shanghai, China

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.